BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of SteadyMed Ltd. (“SteadyMed” or the “Company”) (NASDAQ: STDY) investors concerning the Company and its officers’ possible violations of federal securities laws.
On August 31, 2017, SteadyMed announced that it received a Refusal to File letter from the FDA in connection with its New Drug Application (“NDA”) for Treyvent, a pulmonary arterial hypertension treatment. Based on a preliminary review of the NDA, which was submitted in June of 2017, the FDA determined that the application is not sufficiently complete to permit a substantive review.
On this news, SteadyMed's share price fell 33% on August 31, 2017, thereby injuring investors.
If you purchased SteadyMed securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.